PEAR-TREE: Understanding the usefulness of the PEAR-BIO platform in patients with kidney cancer
For World Cancer Day, Maxine Tran and Matt Williams discuss the PEAR-TREE study, which is registered at the ISRCTN registry.
Maxine Tran graduated from Guy’s and St Thomas’s medical schools and was awarded an MRC clinical training fellowship for her PhD in investigating the role of hypoxia inducible transcription factor in VHL-defective tumors at Imperial College London. She was then appointed an NIHR clinical lecturer in Urology at Cambridge, where she completed her specialist urological surgical training. Currently, Maxine is a Professor of Urology at University College London and honorary consultant urological surgeon at Royal Free London Hospital. She is the academic lead for the specialist center for kidney cancer.
Maxine’s clinical and translational research interest is focused on early-stage kidney cancer, the subset of patients that is growing most rapidly and for which there is the most pressing unmet clinical need for better management and reduction of harm from over-treatment. She is Chief Investigator on three investigator-led NIHR research studies, ‘Nephron Sparing Treatment for small renal masses’ (NEST), ‘Investigating the Facilitators and barriers to Tumor Biopsy in the diagnostic pathway for small renal masses’ (IFIT-B) and ‘Sestamibi nuclear medicine scans in the diagnostic pathway of renal masses’ (multi-MIBI).
Matt Williams studied Medicine in Birmingham and completed most of his postgraduate training in London. He completed his PhD in Computer Science at UCL, based in the CRUK Advanced Computational Lab. He is a Consultant Clinical Oncologist at Imperial College Healthcare NHS Trust and Honorary Senior Fellow at Imperial College, where he leads the Computational Oncology Group. His clinical work is focused on primary and metastatic brain tumors. He led the BrainWear and Capable trials, and is currently leading the BrainApp, BEAT-BREAST and INDIGO Community trials, and the GlioCova and Brain Tumour Data Accelerator projects.
He is the Medical Director for Pear Bio, where he leads work on trial development and clinical uses of the Pear Bio assay.
Maxine’s clinical and translational research interest is focused on early-stage kidney cancer, the subset of patients that is growing most rapidly and for which there is the most pressing unmet clinical need for better management and reduction of harm from over-treatment. She is Chief Investigator on three investigator-led NIHR research studies, ‘Nephron Sparing Treatment for small renal masses’ (NEST), ‘Investigating the Facilitators and barriers to Tumor Biopsy in the diagnostic pathway for small renal masses’ (IFIT-B) and ‘Sestamibi nuclear medicine scans in the diagnostic pathway of renal masses’ (multi-MIBI).
Matt Williams studied Medicine in Birmingham and completed most of his postgraduate training in London. He completed his PhD in Computer Science at UCL, based in the CRUK Advanced Computational Lab. He is a Consultant Clinical Oncologist at Imperial College Healthcare NHS Trust and Honorary Senior Fellow at Imperial College, where he leads the Computational Oncology Group. His clinical work is focused on primary and metastatic brain tumors. He led the BrainWear and Capable trials, and is currently leading the BrainApp, BEAT-BREAST and INDIGO Community trials, and the GlioCova and Brain Tumour Data Accelerator projects.
He is the Medical Director for Pear Bio, where he leads work on trial development and clinical uses of the Pear Bio assay.
Latest posts by Maxine Tran & Matt Williams (see all)